Proactiveinvestors Australia Bard1 Life Sciences Ltd https://www.proactiveinvestors.com.au Proactiveinvestors Australia Bard1 Life Sciences Ltd RSS feed en Thu, 27 Jun 2019 00:22:41 +1000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - BARD1 Life Sciences develops world's first blood test for early detection of breast cancer ]]> https://www.proactiveinvestors.com.au/companies/news/207621/bard1-life-sciences-develops-world-s-first-blood-test-for-early-detection-of-breast-cancer-207621.html BARD1 Life Sciences Ltd’s (ASX:BD1) shares are trading about 114% higher intra-day after developing the world’s first blood test for early detection of breast cancer.

The company’s BARD1 Breast Cancer (BC) test has shown high diagnostic accuracy for the detection of breast cancer across all sub-types and stages.

Importantly, BARD1 BC accurately distinguishes malignant breast cancer from benign lesions.

It is worth noting that no blood tests are currently available for screening or early detection of breast cancer.

The BARD1 BC breakthrough follows the earlier announcement of success with the BARD1 ovarian cancer test.

Great media coverage of @BARD1LSL by @ProactiveInvestors https://t.co/dugd12CsgA https://t.co/ONuB8yZTns

— BARD1 Life Sciences (@BARD1LSL) May 21, 2018

The company now plans to develop both tests in parallel using the same instrumentation platform.

BARD1 BC could be used to screen average-risk asymptomatic women to detect breast cancer earlier, increase screening uptake, improve survival and reduce healthcare costs.

Additionally, BARD1 BC could be used as a diagnostic aid to assess the risk of malignancy of suspicious lesions detected by mammography to determine if a lesion is benign or malignant.

Currently, this can only be achieved with biopsies followed by histopathology-based diagnosis.

 

 

BARD1 chief executive officer Dr Leearne Hinch said: “The new BARD1 Breast Cancer test addresses an unmet need for an accurate, reliable and affordable blood test to detect breast cancer early.

“The global breast cancer diagnostics market was the second largest diagnostic segment (after lung cancer) valued at US$20.1 billion in 2013 and is expected to grow at 8.8% annually to reach US$36.4 billion by 2020, representing a significant global market opportunity for an effective breast cancer screening test.

“BARD1 already has a development program for the game-changing BARD1 Ovarian Cancer test which has shown excellent diagnostic accuracy for early detection of ovarian cancer."

]]>
Tue, 23 Oct 2018 15:41:00 +1100 https://www.proactiveinvestors.com.au/companies/news/207621/bard1-life-sciences-develops-world-s-first-blood-test-for-early-detection-of-breast-cancer-207621.html
<![CDATA[Media files - BARD1 Life Sciences approaching "important milestone" on path to commercialisation ]]> https://www.proactiveinvestors.com.au/companies/stocktube/9323/bard1-life-sciences-approaching-important-milestone-on-path-to-commercialisation-9323.html Fri, 18 May 2018 16:50:00 +1000 https://www.proactiveinvestors.com.au/companies/stocktube/9323/bard1-life-sciences-approaching-important-milestone-on-path-to-commercialisation-9323.html <![CDATA[News - BARD1 Life Sciences signs agreement to develop custom research assay ]]> https://www.proactiveinvestors.com.au/companies/news/197251/bard1-life-sciences-signs-agreement-to-develop-custom-research-assay-197251.html BARD1 Life Sciences Limited (ASX:BD1) has entered into an assay development agreement with Thermo Fisher Scientific for custom research assay development of a multiplex autoantibody test system.

The scope of work includes the transfer of the current BARD1 assay design to Thermo Fisher for optimisation of an autoantibody assay using Thermo Fisher’a ProcartaPlex® Technology for BARD1’s research use.

The first application of the ProcartaPlex® Technology is to the BARD1-Ovarian test that BARD1 plans to develop for detection of ovarian cancer.

The custom research assay development project will commence this month and is expected to take about nine months.

Evaluating the accuracy of the BARD1-Ovarian test

If the development project is successful, BARD1 and Thermo Fisher will then discuss the potential for Thermo Fisher to supply research autoantibody kits to BARD1 for its use in research studies.

BARD1 chief executive officer Dr Leearne Hinch said: “We are pleased to work with such an experienced partner.

“The development of a RUO BARD1 autoantibody assay for use on Luminex® instrumentation will be an important milestone for the company, enabling us to initiate clinical testing to evaluate the accuracy of the new multiplex BARD1-Ovarian test for early detection of ovarian cancer in early 2019.”

READ: BARD1 Life Sciences secures Israeli patent for unique lung cancer test

BARD1 was recently issued a patent in Israel for detecting BARD1 isoforms (proteins) in lung and colorectal cancer.

The company’s proprietary technology platform, BARD1, is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers.

BARD1’s patent portfolio comprises five patent families with multiple granted and pending patents across key markets including the US, Europe and Japan.

]]>
Fri, 18 May 2018 16:19:00 +1000 https://www.proactiveinvestors.com.au/companies/news/197251/bard1-life-sciences-signs-agreement-to-develop-custom-research-assay-197251.html
<![CDATA[News - BARD1 Life Sciences secures Israeli patent for unique lung cancer test ]]> https://www.proactiveinvestors.com.au/companies/news/193513/bard1-life-sciences-secures-israeli-patent-for-unique-lung-cancer-test-193513.html BARD1 Life Sciences Ltd (ASX:BD1) has been issued a patent in Israel for detecting BARD1 isoforms (proteins) in lung and colorectal cancer.

The company’s proprietary technology platform, BARD1, is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers.

READ: Bard1 Life Sciences is one of the ASX’s most active top performers today

The new patent protects the methods for detecting the presence of the specific BARD1 isoforms and methods for treating and/or preventing lung cancer and colorectal cancer.

Commercialising the company’s diagnostic test

The BARD1 lung test is in development for the early detection of lung cancer.

The company is currently in discussions with a number of contract laboratory organisations to transfer its work to date to a commercial platform.

This will enable the BARD1 tests to be performed by most hospital and independent clinical laboratories around the world.

Leading cause of cancer death in Australia

Lung cancer is the fifth most common cancer and the leading cause of cancer death in Australia.

The Australian Institute of Health and Welfare (AIHW) estimates that there will be 12,741 new cases of lung cancer diagnosed (9.2% of all new cancers diagnosed) and 9,198 deaths from lung cancer (18.9% of all cancer deaths) in Australia in 2018.

Early detection of lung cancer can save people’s lives

Lung cancer is often diagnosed at a later stage after it has spread to other parts of the body, resulting in a 15.8% chance of survival after 5-years in Australia.

Early detection of lung cancer has the potential to save people’s lives by enabling earlier treatment when it is potentially curable.

There is currently no approved blood test available for screening of lung cancer in people without symptoms.

BARD1’s patent portfolio comprises five patent families with multiple granted and pending patents across key marketplaces including the US, Europe and Japan.

]]>
Wed, 21 Mar 2018 13:40:00 +1100 https://www.proactiveinvestors.com.au/companies/news/193513/bard1-life-sciences-secures-israeli-patent-for-unique-lung-cancer-test-193513.html
<![CDATA[News - Bard1 Life Sciences is one of the ASX’s most active top performers today ]]> https://www.proactiveinvestors.com.au/companies/news/192812/bard1-life-sciences-is-one-of-the-asxs-most-active-top-performers-today-192812.html Bard1 Life Sciences Ltd (ASX:BD1) is one of the most actively traded stocks on the ASX today with over 88 million shares changing hands around 2.00pm AEST.

Furthermore, the heavy volume in the stock has pushed shares up 22.7%.

Only one other stock has had more shares traded today and that is Blackham Resources Ltd (ASX:BLK) with 280 million shares traded, up 41.5%.

READ: Blackham Resources surges 40% as output increases and costs fall

BARD1 is a biotechnology company developing non-invasive cancer diagnostics.

Earlier this week, the company received additional positive results from the application of its BARD1-Ovarian test.

Testing confirmed high accuracy for detection of ovarian cancer with 89% sensitivity and 82% specificity.

Commercialising the company’s diagnostic test

BARD1 is currently in discussions with a number of contract laboratory organisations to transfer its work to date to a commercial platform.

This will enable the BARD1 tests to be performed by most hospital and independent clinical laboratories around the world.

Opportunity the ovarian cancer market presents

The global ovarian cancer diagnostics market was valued at US$7.2 billion in 2013.

It was expected to grow at 7.2% annually to reach US$11.8 billion by 2020.

There is a clear unmet clinical need for non-invasive, accurate and affordable diagnostic tests for the early detection and monitoring of ovarian cancer.

]]>
Thu, 08 Mar 2018 14:34:00 +1100 https://www.proactiveinvestors.com.au/companies/news/192812/bard1-life-sciences-is-one-of-the-asxs-most-active-top-performers-today-192812.html
<![CDATA[News - BARD1 Life Sciences Ltd raising funds for novel cancer diagnostics ]]> https://www.proactiveinvestors.com.au/companies/news/180350/bard1-life-sciences-ltd-raising-funds-for-novel-cancer-diagnostics-180350.html BARD1 Life Sciences Ltd (ASX:BD1) has received binding commitments to raise $1,097,325 via the issue of shares to sophisticated and professional investors at an issue price of $0.008 per share.

The company will also conduct a share purchase plan (SPP) for eligible shareholders to raise up to a further $1 million at the same issue price.

Funds raised from the placement and SPP will be used to fund ongoing research and development programs, commercial initiatives and for general working capital purposes.

BARD1 is an Australian life sciences company developing novel diagnostics and therapeutics for unmet needs in cancer.

The company’s proprietary BARD1 Technology is based on BARD1, a potent tumour suppressor in healthy individuals and an important tumour biomarker in cancer.

BARD1’s lead product, the BARD1 Lung Cancer Test, is a non-invasive blood test in development for early detection of lung cancer.

The company is also researching a high-value pipeline of potential diagnostic and therapeutic products for multiple cancers.

BARD1’s research activities are currently performed under a research contract at the University of Geneva (UNIGE).

The company’s business strategy is to focus on leveraging its BARD1 Technology to develop diagnostic tests for early detection of cancer where there are clear unmet needs and product advantages.

]]>
Wed, 05 Jul 2017 15:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/180350/bard1-life-sciences-ltd-raising-funds-for-novel-cancer-diagnostics-180350.html
<![CDATA[News - BARD1 Life Sciences Ltd targets cash injection ]]> https://www.proactiveinvestors.com.au/companies/news/180172/bard1-life-sciences-ltd-targets-cash-injection-180172.html BARD1 Life Sciences Ltd (ASX:BD1) is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.

The company is focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer.

The halt will remain in place until the opening of trade on Wednesday 5th July 2017, or earlier if an announcement is made to the market.

]]>
Mon, 03 Jul 2017 10:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/180172/bard1-life-sciences-ltd-targets-cash-injection-180172.html
<![CDATA[News - BARD1 Life Sciences shares surge after positive ovarian cancer test ]]> https://www.proactiveinvestors.com.au/companies/news/175261/bard1-life-sciences-shares-surge-after-positive-ovarian-cancer-test-175261.html BARD1 Life Sciences (ASX:BD1) shares were trading 110% higher intra-day after successfully completing a clinical trial of its proprietary ovarian cancer diagnostic test.

The trial involving 348 samples (200 women with ovarian cancer and 148 controls) found the test to have both high specificity (87%) and high sensitivity (90%).

In addition, the test detected all subtypes and stages of ovarian cancer in the samples with the performance of the test between early-stage and late stage ovarian cancer not statistically different.

The BARD1 Ovarian Cancer Test is an ELISA-based blood test that uses a panel of peptides on a solid surface.

When exposed to a blood sample, the test measures the binding of antibodies in the patient’s blood to these peptides.

Previous data from smaller scale studies had already established the proof of concept of the test and initial indications of high sensitivity and specificity.

With high levels of accuracy shown to all stages of ovarian cancer, the BARD1 test may offer a substantial improvement over existing ovarian cancer blood tests.

The test is expected to improve the accurate detection of cancer at all stages with few false positives.

Further studies are planned to demonstrate the use of the BARD1 Ovarian Cancer Test for distinction of benign ovarian lesions and cancer.

The company is also focused on its lead product, the BARD1 Lung Cancer Test, for early detection of lung cancer utilising novel tumour markers and a proprietary algorithm.

BARD1’s closing cash balance as at 31 December 2016 was circa $1.93 million.

]]>
Thu, 23 Mar 2017 12:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/175261/bard1-life-sciences-shares-surge-after-positive-ovarian-cancer-test-175261.html